Acentrus Specialty has finalized an agreement with Chiasma, Inc. to provide qualified Acentrus clients access to MYCAPSSA® (octreotide), delayed-release oral capsules for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. Participation in Acentrus is open to hospital organizations of all sizes, types and affiliations. Clients, which range from academic medical centers to community-based hospitals, share one goal: to provide their patients with high-quality care in a setting where clinical and pharmacy services are integrated. There is no cost for an organization to join the Acentrus network, which provides 115 health systems and hospitals with the following benefits: Access to difficult-to-obtain specialty medications; Data management; Collaboration with health system peers dedicated to sharing best practices. Portfolio of other services to help hospital-based specialty pharmacies meet the needs of their patients, including backup and contract pharmacy as well as expertise in licensing and accreditation.